+

Namita Thapar On Emcure IPO Triumph: 'Mirza Ghalib' Captures Her Emotions

In a heartfelt post on social media platform X (formerly Twitter), Namita Thapar, Executive Director of Emcure Pharmaceuticals Ltd, expressed her emotions following the company’s successful stock market debut. The company was listed at a notable 31% price premium. Thapar wrote, “Emotional morning today… we got listed at NSE 🙂 68 times oversubscribed, listed at […]

Namita Thapar On Emcure IPO Triumph: 'Mirza Ghalib' Captures Her Emotions
Namita Thapar On Emcure IPO Triumph: 'Mirza Ghalib' Captures Her Emotions

In a heartfelt post on social media platform X (formerly Twitter), Namita Thapar, Executive Director of Emcure Pharmaceuticals Ltd, expressed her emotions following the company’s successful stock market debut. The company was listed at a notable 31% price premium. Thapar wrote, “Emotional morning today… we got listed at NSE 🙂 68 times oversubscribed, listed at 31% price premium but my Mirza Ghalib shayari sums up my feelings… congratulations Team Emcure!” Accompanying her message was a video where she recited Mirza Ghalib’s verse: “Hazaaron khwahishen aisi ke har khwahish pe dam nikle, bohat niklay mere armaan, lekin phir bhi kam nikle.”


Emcure Pharmaceuticals made its market entry at ₹1,325.05 per share, reflecting a 31.45% increase on both the BSE and NSE on July 10. The stock concluded the trading session with a premium exceeding 35% compared to the issue price of ₹1,008. On the BSE, 12.62 lakh shares of Emcure Pharmaceuticals were traded, while the NSE saw a trading volume of 140.08 lakh shares. Consequently, the company’s market capitalization reached ₹25,695.63 crore on Wednesday.

Emcure Pharmaceuticals’ IPO Success

The ₹1,952 crore initial public offering (IPO) of Emcure Pharmaceuticals garnered 67.87 times subscription by the end of the offer period. Supported by Bain Capital, the IPO was priced between ₹960 and ₹1,008 per share. It included a fresh issue of equity shares worth ₹800 crore and an offer for sale (OFS) of 1.14 crore shares valued at ₹1,152 crore. The proceeds from the IPO are earmarked for debt repayment and general corporate purposes.

Emcure Pharmaceuticals specializes in the development, manufacturing, and global marketing of a diverse range of pharmaceutical products. The successful listing marks a significant milestone for the company and highlights its strong market presence and investor confidence.

Tags:

EmcureNamita ThaparTDGThe Daily Guardian